Icn Pharmaceuticals, Inc.

Other

Ardea Biosciences, Inc

Ribapharm Inc.

Valeant Pharmaceuticals International

Valeant Pharmaceuticals North America

Valeant Research and Development

Robert C Tam

Devron R Averett

Guangyi Wang

Kandasamy Ramasamy

Zhi Hong

Huanming Chen

Andreas Maderna

Johnson Lau

Kanda S Ramasamy

Stanley Lang

Kanda Ramasamy

Dinesh Barawkar

Varaprasad Chamakura

Hassan El Abdellaoui

Anneke K Raney

Hassan Abdellaoui

The invention concerns compounds which inhibit MEK and which have activity as anti-neoplastic agents. These compounds include N-substituted-3-hydroxy-5-arylamino-isothiazole-4-carboxamidines. Also included are the tautomeric isothiazol-3(2H)-ones.

Phenylamino isothiazole carboxamidines as MEK inhibitors

Novel nucleoside analog compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.

Nucleoside analogs with carboxamidine modified monocyclic base

This application relates to novel fused tricyclic thienopyridines of Formulas I and II, which useful for treating Hepatitis B infection and other diseases. This application also relates to pharmaceutical compositions comprising thienopyridines and to the use of such compositions to treat Hepatitis B and other diseases.

Heterocyclic compounds having anti-HBV activity

Novel heterocyclic aromatic compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.

Tirazole nucleoside analogs and methods for using same

Aptamer oligonucleotides specifically bind to the DNA binding site of proteins such as Sp1 and Sp1-related proteins which regulate the genes which encode costimulatory molecules such as CD28 and cytokines such as IL-2 and GMCSF. The oligonucleotides compete with the DNA-binding sites of regulatory proteins which specifically regulate molecules to modulate T-cell activation. This serves to modulate gene expression by preventing transcription of the gene. Aptamers are administered to provide therapies for diseases which involve aberrant T-cell activation such as psoriasis, Type I (insulin-dependent) diabetes mellitus, multiple sclerosis, autoimmune uveitis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease (Crohn's and ulcerative colitis), and septic shock and to regulate normal T-cell activation such as in allograft rejection.

G-rich oligo aptamers and methods of modulating an immune response

Compositions and methods for pyrrolo&lsqb;2,3-d&rsqb;pyrimidine nucleoside analogs having substituents at the C4&prime; and C5&prime; positions of the ribofuranose moiety are presented. Contemplated compositions exhibit, among other things, anti-cancer and immunomodulating effects at reduced cytotoxicity.

Pyrrolo&lsqb;2,3-d&rsqb;pyrimidine nucleoside analogs

Monocyclic L-nucleosides, analogs and uses thereof

Moncyclic L-nucleosides analogs

A 1-(&bgr;-L-ribofuranosyl)-1,2,4-triazole-3-carboxamide is administered in a method of treatment of a viral infection in a patient, including HIV infection, HCV infection, or BHV infection.

Treatment of viral infections using the L-isomer of ribavirin

Novel purine L-nucleoside compounds are disclosed, in which both the purine rings and the sugar are either modified, functionalized or both. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Th1 and Th2.

Purine L-nucleosides, analogs and uses thereof

Novel nucleosides having the structure of Formula 1 and Formula 2 are contemplated. In one aspect of the invention, controlled release dosage forms are particularly contemplated. Further, alternative routes of administration of the nucleosides having the structure of Formula 1 or Formula 2 are contemplated.

Growing community of inventors

Costa Mesa, CA, United States of America

Robert C Tam